Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

ESSENTIAL READING

  • Biopharma, Payers, Institutional

Outcomes Based Arrangements in Biopharma

Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
  • Biopharma

A few thoughts about navigating biopharma macro scenarios

Planning biopharma strategies against a robust set of macro-scenarios will be crucial to mid- and long-term success. While historically these scenarios have revolved around targeted issues, the current challengescall for a more expansive - and likely more difficult - set of questions to be asked.
  • Biopharma, Payers, Providers, Medtech, Digital

Why the Best AI Won’t Win in Healthcare

As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.
Sector
All
NEJM opinion

Buying kit for a leadership position in the @Home revolution? Implications of Optum’s acquisition of naviHealth

  • Payers , 
  • Providers
Summary NaviHealth is a leader in post-acute care management; since i…

Read more

Covid’s backhand blow: payer mix degradation and the threat of renewed payer/provider rate brawls

  • Payers , 
  • Providers
Among Covid’s many repercussions, the recession shock will drive a sus…

Read more

Medicare Advantage’s durable – but underexplained – post-acute care advantage

  • Payers , 
  • Providers
Health Affairs has put out another study – this one by Skopec and team…

Read more

Covid and the rest: An opinionated take on NEJM highlights for April 2020

  • NEJM
Hydroxychloroquine does not seem to help much in Covid-19 (with caveat…

Read more

Strategy in the Time of Covid

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital , 
Preamble A recent post from Recon Strategy outlined the longer-term st…

Read more

The day after: Implications for hospitals, payers, biotech and more…

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital
Even as our priority today is dealing with the Covid crisis, healthcar…

Read more

The infectiologists have the floor: An opinionated take on NEJM highlights for March 2020

  • NEJM
A first Covid-19 interventional study – unfortunately negative The fir…

Read more

Coronavirus and more: An opinionated take on NEJM highlights for January/February 2020

  • NEJM
Keeping up with COVID-19 It’s not easy for a refereed weekly print per…

Read more

Tax dollars doing good work: An opinionated take on NEJM highlights for December 2019

  • NEJM
The loneliness of the patent-less drug Colchicine is a very old drug c…

Read more

SELECTED ENGAGEMENTS

Insight, put to work

Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.

  • Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

  • Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

  • Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint

Keep up with Recon Strategy Insights
Get an email each time we publish a new article